Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,320 recruiting studies in this area right now.
By phase
- Not applicable9,604
- Phase 24,428
- Phase 12,683
- Phase 1/Phase 21,650
- Phase 31,400
- Phase 2/Phase 3287
- Phase 4268
Top conditions
- Breast Cancer1,207
- Prostate Cancer646
- Cancer638
- Colorectal Cancer479
- Lung Cancer421
- Ovarian Cancer342
- Multiple Myeloma329
- Pancreatic Cancer288
- Gastric Cancer285
- Acute Myeloid Leukemia283
- Hepatocellular Carcinoma257
- Solid Tumor246
- Advanced Solid Tumor232
- Head and Neck Cancer228
- Cervical Cancer226
- Endometrial Cancer214
- Advanced Solid Tumors207
- Esophageal Cancer192
Leading sponsors
- M.D. Anderson Cancer Center455
- Fudan University305
- National Cancer Institute (NCI)294
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University275
- Mayo Clinic237
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences145
- AstraZeneca132
- Ruijin Hospital128
Where studies are running
- California1,397
- Texas632
- Arizona508
- Florida436
- Alabama430
- New York405
- Massachusetts340
- Maryland331
- New Jersey275
- Pennsylvania235
Recruiting studies20,320 total
- NCT05851677Recruiting
Study of disitamab vedotin for breast cancer
This trial studies disitamab vedotin (also called RC48-ADC) in people with breast cancer. It is mainly for patients who have already used this specific drug, to see how well it works as part of the study.
ShanghaiAges Any age - NCT05838729RecruitingPhase 1/Phase 2
RiMO-301 plus radiation with PD-1 therapy for head-neck cancer
This trial studies RiMO-301 injection combined with palliative radiation and a PD-1 immune therapy (pembrolizumab or nivolumab) for head and neck cancer that cannot be fully removed. It aims to see whether this approach can shrink tumors and improve outcomes safely.
Chicago, IllinoisAges 18 years+ - NCT06152731RecruitingPhase 2
HRD testing for advanced ovarian cancer
This study collects tumor samples from people newly diagnosed with advanced ovarian cancer to test for HRD, a genetic feature that may help doctors predict which treatments work best. The goal is to see if HRD testing can guide future treatment decisions for patients like you.
AmiensAges 18 years+ - NCT06367920Recruiting
Study of brain MRI data in children with developmental delay
This study looks back at medical records of children and young adults (up to age 20) who had brain MRIs to understand developmental delays. It aims to gather information that could help improve care for kids with similar conditions.
Seongnam-si, Gyeonggi-doAges Up to 20 years - NCT06241612RecruitingPhase 3
Personalized neck radiation for nasopharyngeal cancer
This trial tests whether giving radiation only to the specific lymph nodes that need it works as well as standard radiation for people with nasopharyngeal cancer. It aims to reduce side effects while still controlling the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06388720RecruitingPhase 2
Two chemotherapy drugs for bladder cancer after BCG
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
Goyang-siAges 20 years+ - NCT06380751RecruitingPhase 3
New targeted therapy for BRCA/PALB2-mutated HR+ breast cancer
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Gilbert, ArizonaAges 18 years+ - NCT06386146RecruitingPhase 1/Phase 2
New pill for advanced cancers with TP53 Y220C mutation
This trial tests a new pill called JAB-30355 for people with advanced cancers that have a specific genetic change (TP53 Y220C). It's for those who have already tried other treatments and are looking for a new option.
Denver, ColoradoAges 18 years+ - NCT06393738RecruitingPhase 1
ARV-393 for relapsed or refractory non-Hodgkin lymphoma
This study tests a new oral medication (ARV-393) for people with certain types of non-Hodgkin lymphoma that have returned or not responded to previous treatments. The drug is designed to target a protein inside cancer cells to make them stop growing and die.
New Haven, ConnecticutAges 18 years+ - NCT06394869Recruiting
Testing a urine test to reduce the need for bladder scopes for invisible blood in urine
This study tests a new urine test called Cxbladder Triage Plus. The goal is to see if using this test can help some people avoid an unnecessary cystoscopy (a scope placed into the bladder) when they have invisible blood in their urine.
Homewood, AlabamaAges 18–88 - NCT06391749Enrolling by invitation
Blood test for multiple cancers in people with symptoms
This trial tests a new blood test (SPOT-MAS) that looks for signs of multiple cancers in people who already have symptoms and are being checked with imaging. If the blood test is positive, you'll get more detailed scans or a biopsy to see if cancer is present.
Ho Chi Minh CityAges 18 years+ - NCT06392386RecruitingPhase 2/Phase 3
Efgartigimod for children with generalized myasthenia gravis
This study tests an investigational drug called efgartigimod for children and teens with generalized myasthenia gravis. It may help those who haven't responded well enough to standard treatments.
Charlotte, North CarolinaAges 2–17 - NCT06397963Recruiting
Personalized immune cell therapy for advanced solid tumors
This study tests a new treatment using your body's own immune cells (called tumor-infiltrating lymphocytes) that are taken from your tumor, grown in a lab, and then put back into you. It's for people with advanced solid tumors who have run out of standard options.
Beijing, Beijing MunicipalityAges 18–70 - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT06398418RecruitingPhase 1
Study of R-5780 with PD-1 drugs for advanced solid tumors
This trial tests a new drug called R-5780 combined with standard immunotherapy (PD-1 checkpoint inhibitors) for people with advanced skin cancers or other solid tumors that have stopped responding to treatment. The goal is to see if this combination is safe and helps fight the cancer.
Denver, ColoradoAges 18–80 - NCT06384807RecruitingPhase 1/Phase 2
Study of BHV-1510 for advanced solid tumors
This trial tests a new drug, BHV-1510, alone or combined with another drug (cemiplimab), for people with advanced solid tumors that haven't responded to other treatments. It's for those who are still in fairly good health and have not had certain prior treatments.
Duarte, CaliforniaAges 18 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Los Angeles, CaliforniaAges 6 months–25 years - NCT06385925RecruitingPhase 1/Phase 2
Study of TSN1611 for cancers with KRAS G12D mutation
This trial tests a new drug called TSN1611 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or stop them from growing.
Houston, TexasAges 18–75 - NCT06389292RecruitingPhase 3
Study of Lisaftoclax plus azacitidine for new AML
This study tests a new pill (APG-2575, also called Lisaftoclax) combined with a standard injection (azacitidine) for adults with newly diagnosed AML who cannot take strong chemotherapy. The goal is to see if this combination works better than treatment alone.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06392477RecruitingPhase 1
Testing a new drug for relapsed B-cell lymphoma
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
Camperdown, New South WalesAges 18 years+ - NCT06393374RecruitingPhase 3
Study of a new drug combination for residual TNBC after initial treatment
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
Mobile, AlabamaAges 18 years+ - NCT06387082RecruitingPhase 1
Study of an investigational pill for certain leukemias
This study tests an experimental pill (HMPL-506) for people with certain types of leukemia (AML or ALL) that have not responded to standard treatments. The pill targets specific gene changes (MLL rearrangement or NPM1 mutation) to try to kill the cancer cells.
ChangshaAges 18 years+ - NCT06384352RecruitingPhase 1
Study of YL211 for advanced solid tumors
This trial tests a new drug, YL211, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for cancers like lung, colorectal, stomach, pancreatic, liver, bile duct, and head and neck cancers.
Aurora, ColoradoAges 18 years+ - NCT06385080RecruitingPhase 1/Phase 2
Study of amivantamab for head and neck cancer
This trial tests a drug called amivantamab, either alone or with other treatments, for people with head and neck cancer that has spread or come back. The goal is to see if the drug can help shrink tumors or control the cancer.
La Jolla, CaliforniaAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,320 recruiting oncology studies from the U.S. registry right now, out of 31,393 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.